Contract awarded for products that bring improvement to healthcare industry
London /PRNewswire/ - Smith+Nephew (LSE: SN, NYSE: SNN), the global medical technology company, today announces its PICO Single Use Negative Pressure Wound Therapy Systems have received an Innovative Technology contract from Vizient, Inc. the nation's largest member-driven health care performance improvement company. The contract was awarded based on the recommendation of the PICO Single Use Negative Pressure Wound Therapy Systems by hospital experts who serve on one of Vizient's member-led councils, and it signifies to Vizient members unique qualities that potentially bring improvement to the healthcare industry.
Innovative Technology contracts are recommended after review and interaction with products submitted through Vizient's Innovative Technology Program. Vizient member-led councils identify technologies that have the potential to enhance clinical care, patient safety, health care worker safety or improve business operations of health care organizations.
The PICO sNPWT System provides a portable, easy to use, canister-free design and is equipped with the comfort and mobility of Smith+Nephew soft port technology. This proprietary, silicone-based, four-layer technology uniquely manages wound fluid by simultaneously evaporating and locking it away, keeping excess moisture away from the wound and periwound area.1
This technology also offers expansion of NPWT benefits beyond the wound site by providing compression to the periwound area, which may help improve perfusion.2
The PICO System received this award after being cleared by the Food and Drug Administration (FDA) as the first sNPWT system indicated to aid in reducing the incidence of superficial and deep incisional surgical site infections (SSIs) for high-risk patients in Class I and Class II wounds, post-operative Seroma, and Dehiscence.
"We are thrilled that our PICO System has been recognized by healthcare experts in receiving this distinguished Innovative Technology contract in the US. Surgical site complications continue to be costly events that plague our patients and healthcare systems. "Our PICO technology has been shown to reduce the risk of SSIs across multiple specialties, improving patient care and helping get them home sooner" said Laura Ackerman, Vice President and General Manager, NPWT at Smith+Nephew. "We are committed to innovating the standard of care for patients, and this recognition of the PICO System by Vizient further validates that commitment."
Malmsjö, M., Huddleston, E., & Martin, R. (2014). Biological effects of a disposable, canisterless Negative Pressure Wound Therapy system (in-vitro). Eplasty, 14: e15.
Sugrue, Michael et al. 2016. "World Union of Wound Healing Societies (WUWHS) Consensus Document. Closed Surgical Incision Management: Understanding the Role of NPWT." Wounds International.
Vizient represents a diverse membership that includes academic medical centers, pediatric facilities, community hospitals, integrated health delivery networks and non-acute healthcare providers and represents approximately $130 billion in annual purchasing volume. Through its Innovative Technology Program, Vizient works with member-led councils and task forces to evaluate products for their potential to bring real innovation to healthcare. Vizient may award a contract to products deemed worthy of the Innovative Technology designation outside of the competitive bid cycle.
Smith+Nephew is a portfolio medical technology company focused on the repair, regeneration and replacement of soft and hard tissue. We exist to restore people's bodies and their self-belief by using technology to take the limits off living. We call this purpose 'Life Unlimited'. Our 19,000 employees deliver this mission every day, making a difference to patients' lives through the excellence of our product portfolio, and the invention and application of new technologies across our three global franchises of Orthopaedics, Sports Medicine & ENT and Advanced Wound Management.
Founded in Hull, UK, in 1856, we now operate in more than 100 countries, and generated annual sales of $5.2 billion in 2022. Smith+Nephew is a constituent of the FTSE100 (LSE: SN, NYSE: SNN). The terms 'Group' and 'Smith+Nephew' are used to refer to Smith & Nephew plc and its consolidated subsidiaries, unless the context requires otherwise.
For more information about Smith+Nephew, please visit www.smith-nephew.com and follow us on Twitter, LinkedIn, Instagram or Facebook.
This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading margins, market trends and our product pipeline are forward-looking statements. Phrases such as "aim", "plan", "intend", "anticipate", "well-placed", "believe", "estimate", "expect", "target", "consider" and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith+Nephew, these factors include: risks related to the impact of Covid, such as the depth and longevity of its impact, government actions and other restrictive measures taken in response, material delays and cancellations of elective procedures, reduced procedure capacity at medical facilities, restricted access for sales representatives to medical facilities, or our ability to execute business continuity plans as a result of Covid; economic and financial conditions in the markets we serve, especially those affecting healthcare providers, payers and customers (including, without limitation, as a result of Covid); price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls or other problems with quality management systems or failure to comply with related regulations; litigation relating to patent or other claims; legal and financial compliance risks and related investigative, remedial or enforcement actions; disruption to our supply chain or operations or those of our suppliers (including, without limitation, as a result of Covid); competition for qualified personnel; strategic actions, including acquisitions and dispositions, our success in performing due diligence, valuing and integrating acquired businesses; disruption that may result from transactions or other changes we make in our business plans or organisation to adapt to market developments; relationships with healthcare professionals; reliance on information technology and cybersecurity; disruptions due to natural disasters, weather and climate change related events; changes in customer and other stakeholder sustainability expectations; changes in taxation regulations; effects of foreign exchange volatility; and numerous other matters that affect us or our markets, including those of a political, economic, business, competitive or reputational nature. Please refer to the documents that Smith+Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith+Nephew's most recent annual report on Form 20-F, which is available on the SEC's website at www. sec.gov, for a discussion of certain of these factors. Any forward-looking statement is based on information available to Smith+Nephew as of the date of the statement. All written or oral forward-looking statements attributable to Smith+Nephew are qualified by this caution. Smith+Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith+Nephew's expectations.
™ Trademark of Smith+Nephew. Certain marks registered in US Patent and Trademark Office.